^
    8ms
    Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MUC16 expression
    |
    cyclophosphamide • fludarabine IV • JCAR020
    over1year
    Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MUC16 expression
    |
    cyclophosphamide • fludarabine IV • JCAR020
    over3years
    Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 18 | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MUC16 expression
    |
    fludarabine IV • JCAR020
    4years
    Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MUC16 expression
    |
    fludarabine IV • JCAR020
    over4years
    A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) (SGO 2020)
    An additional cohort was treated at dose level 3 (3 × 106 CAR T cells/kg) following pretreatment with cyclophosphamide/fludarabine... IV and IP IL-12 secreting MUC16ecto-targeted CAR T cells were safely administered in the absence of chemotherapy. Toxicity was observed when the CAR T cells were given post-lymphodepleting chemotherapy. Dose escalation of CAR T cells will continue to dose level 5 (3 × 107 CAR T cells/kg).
    Clinical • P1 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    fludarabine IV • JCAR020